{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T20:21:00Z","timestamp":1789330860475,"version":"build-2803163510"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Melanoma of unknown primary (MUP) is a rare subtype of melanoma, with its low incidence posing challenges for clinical management. This systematic review integrates recent advances in MUP research, with a focus on pathogenesis, molecular characteristics, and therapeutic strategies. The proposed pathogenesis involves spontaneous regression of the primary lesion, potentially driven by sequential immune responses mediated by T cells and natural killer cells. At the molecular level, whole-exome\/genome analyses reveal that MUP and cutaneous melanoma share a highly concordant UV damage-driven mutational landscape; nevertheless, MUP exhibits distinct genomic alterations, including recurrent mutations in the telomerase reverse transcriptase promoter, protein phosphatase 6 catalytic subunit, and isocitrate dehydrogenase 1. Current therapeutic approaches are similar to those for advanced melanoma, encompassing surgery, immune checkpoint inhibitors (ICIs), and targeted therapies. While ICIs have demonstrated significant improvements in survival, the clinical efficacy of targeted therapies in MUP remains to be fully established. By consolidating current knowledge, this review provides insights to guide diagnosis, treatment, and future research in MUP.<\/jats:p>","DOI":"10.1093\/oncolo\/oyaf410","type":"journal-article","created":{"date-parts":[[2025,12,10]],"date-time":"2025-12-10T13:15:28Z","timestamp":1765372528000},"source":"Crossref","is-referenced-by-count":2,"title":["Melanoma of unknown primary: a comprehensive review of immune-mediated pathogenesis and therapies"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2509-1706","authenticated-orcid":false,"given":"Wanling","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Emergency, The First Hospital of Jilin University , Changchun, 130021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Gui","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University , Changchun, 130021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengna","family":"Guo","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University , Changchun, 130021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University , Changchun, 130021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1870-798X","authenticated-orcid":false,"given":"Di","family":"Wu","sequence":"additional","affiliation":[{"name":"Cancer Center, The First Hospital of Jilin University , Changchun, 130021,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,13]]},"reference":[{"key":"2026010223413856300_oyaf410-B1","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2026010223413856300_oyaf410-B2","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.critrevonc.2010.04.007","article-title":"Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature","volume":"78","author":"Kamposioras","year":"2011","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026010223413856300_oyaf410-B3","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1200\/JCO.2007.14.0285","article-title":"Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma","volume":"26","author":"Lee","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026010223413856300_oyaf410-B4","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/00000658-195212000-00001","article-title":"End results in the treatment of malignant melanoma; a report of 1190 cases","volume":"136","author":"Pack","year":"1952","journal-title":"Ann Surg"},{"key":"2026010223413856300_oyaf410-B5","first-page":"341","article-title":"Malignant melanoma of unknown primary origin","volume":"117","author":"Dasgupta","year":"1963","journal-title":"Surg Gynecol Obstet"},{"key":"2026010223413856300_oyaf410-B6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/1097-0142(196511)18:11<1399::AID-CNCR2820181104>3.0.CO;2-R","article-title":"Spontaneous regression of primary malignant melanomas with regional metastases","volume":"18","author":"Smith","year":"1965","journal-title":"Cancer"},{"key":"2026010223413856300_oyaf410-B7","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1097\/00000478-198702000-00008","article-title":"Malignant melanoma primary in lymph node. The case of the missing link","volume":"11","author":"Shenoy","year":"1987","journal-title":"Am J Surg Pathol"},{"key":"2026010223413856300_oyaf410-B8","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/1097-0142(197701)39:1<164::AID-CNCR2820390127>3.0.CO;2-T","article-title":"Nevus cell aggregates associated with lymph nodes: estimated frequency and clinical significance","volume":"39","author":"Ridolfi","year":"1977","journal-title":"Cancer"},{"key":"2026010223413856300_oyaf410-B9","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2559.1992.tb00988.x","article-title":"Histological regression in primary cutaneous melanoma: recognition, prevalence and significance","volume":"20","author":"Blessing","year":"1992","journal-title":"Histopathology"},{"key":"2026010223413856300_oyaf410-B10","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jamadermatol.2013.9856","article-title":"Correlation of histologic regression in primary melanoma with sentinel node status","volume":"150","author":"Botella-Estrada","year":"2014","journal-title":"JAMA Dermatol"},{"key":"2026010223413856300_oyaf410-B11","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/DAD.0b013e318165641a","article-title":"Complete regression of primary malignant melanoma","volume":"30","author":"Emanuel","year":"2008","journal-title":"Am J Dermatopathol"},{"key":"2026010223413856300_oyaf410-B12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jamcollsurg.2003.08.012","article-title":"Endogenous immune response to early- and intermediate-stage melanoma is correlated with outcomes and is independent of locoregional relapse and standard prognostic factors","volume":"198","author":"Litvak","year":"2004","journal-title":"J Am Coll Surg"},{"key":"2026010223413856300_oyaf410-B13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/1523-1747.ep12479662","article-title":"Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma","volume":"97","author":"Tefany","year":"1991","journal-title":"J Invest Dermatol"},{"key":"2026010223413856300_oyaf410-B14","doi-asserted-by":"crossref","first-page":"631","DOI":"10.21873\/anticanres.16199","article-title":"Spontaneous regression of swine melanoma: the role of tumour-infiltrating T and NK cells","volume":"43","author":"Planska","year":"2023","journal-title":"Anticancer Res"},{"key":"2026010223413856300_oyaf410-B15","doi-asserted-by":"crossref","first-page":"e004310","DOI":"10.1136\/jitc-2021-004310","article-title":"Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary","volume":"10","author":"Tarhini","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026010223413856300_oyaf410-B16","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/labinvest.2017.8","article-title":"Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance","volume":"97","author":"Aung","year":"2017","journal-title":"Lab Invest"},{"key":"2026010223413856300_oyaf410-B17","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/cells11091502","article-title":"Crocin inhibits angiogenesis and metastasis in Colon cancer via TNF-\u03b1\/NF-kB\/VEGF pathways","volume":"11","author":"Bakshi","year":"2022","journal-title":"Cells"},{"key":"2026010223413856300_oyaf410-B18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.pathol.2019.04.001","article-title":"Phenotypic characterisation of immune cells associated with histological regression in cutaneous melanoma","volume":"51","author":"Osella-Abate","year":"2019","journal-title":"Pathology"},{"key":"2026010223413856300_oyaf410-B19","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.humpath.2011.02.019","article-title":"Association between natural killer cells and regression in melanocytic lesions","volume":"42","author":"McKay","year":"2011","journal-title":"Hum Pathol"},{"key":"2026010223413856300_oyaf410-B20","doi-asserted-by":"crossref","first-page":"5416843","DOI":"10.1155\/2020\/5416843","article-title":"FOXP3 in melanoma with regression: between tumoral expression and regulatory T cell upregulation","volume":"2020","author":"Cioplea","year":"2020","journal-title":"J Immunol Res"},{"key":"2026010223413856300_oyaf410-B21","doi-asserted-by":"crossref","DOI":"10.3390\/genes10110915","article-title":"Melanoma-Bearing libechov minipig (MeLiM): the unique swine model of hereditary metastatic melanoma","volume":"10","author":"Horak","year":"2019","journal-title":"Genes (Basel)"},{"key":"2026010223413856300_oyaf410-B22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.dci.2018.10.001","article-title":"The role of \u03b1\u03b2 T-cells in spontaneous regression of melanoma tumors in swine","volume":"92","author":"Cizkova","year":"2019","journal-title":"Dev Comp Immunol"},{"key":"2026010223413856300_oyaf410-B23","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1172\/JCI36022","article-title":"NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo","volume":"119","author":"Lakshmikanth","year":"2009","journal-title":"J Clin Invest"},{"key":"2026010223413856300_oyaf410-B24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-800267-4.00003-1","article-title":"Recognition of tumors by the innate immune system and natural killer cells","volume":"122","author":"Marcus","year":"2014","journal-title":"Adv Immunol"},{"key":"2026010223413856300_oyaf410-B25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000328505","article-title":"NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions","volume":"3","author":"Morgado","year":"2011","journal-title":"J Innate Immun"},{"key":"2026010223413856300_oyaf410-B26","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1200\/JCO.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol"},{"key":"2026010223413856300_oyaf410-B27","doi-asserted-by":"crossref","first-page":"6437057","DOI":"10.1155\/2020\/6437057","article-title":"Research progress on NK cell receptors and their signaling pathways","volume":"2020","author":"Chen","year":"2020","journal-title":"Mediators Inflamm"},{"key":"2026010223413856300_oyaf410-B28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK cell platform for cancer immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"2026010223413856300_oyaf410-B29","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","article-title":"A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments","volume":"24","author":"Barry","year":"2018","journal-title":"Nat Med"},{"key":"2026010223413856300_oyaf410-B30","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.7150\/thno.18752","article-title":"Exosomes derived from natural killer cells exert therapeutic effect in melanoma","volume":"7","author":"Zhu","year":"2017","journal-title":"Theranostics"},{"key":"2026010223413856300_oyaf410-B31","doi-asserted-by":"crossref","first-page":"4859","DOI":"10.1158\/1078-0432.CCR-21-0851","article-title":"Memory-like differentiation enhances NK cell responses to melanoma","volume":"27","author":"Marin","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026010223413856300_oyaf410-B32","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00000372-200012000-00002","article-title":"A zonal comparison of MIB1-Ki67 immunoreactivity in benign and malignant melanocytic lesions","volume":"22","author":"Li","year":"2000","journal-title":"Am J Dermatopathol"},{"key":"2026010223413856300_oyaf410-B33","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.humpath.2013.02.007","article-title":"Value of melanocytic-associated immunohistochemical markers in the diagnosis of malignant melanoma: a review and update","volume":"45","author":"Ord\u00f3\u00f1ez","year":"2014","journal-title":"Hum Pathol"},{"key":"2026010223413856300_oyaf410-B34","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(94)91709-4","article-title":"The role of tyrosinase in autoimmune vitiligo","volume":"344","author":"Song","year":"1994","journal-title":"Lancet"},{"key":"2026010223413856300_oyaf410-B35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02737633","article-title":"The clinical significance of antityrosinase antibodies in melanoma and related hypopigmentary lesions","volume":"16","author":"Merimsky","year":"1998","journal-title":"Clin Rev Allergy Immunol"},{"key":"2026010223413856300_oyaf410-B36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1002\/ijc.2910160504","article-title":"Humoral cytotoxicity in melanoma patients and its correlation with the extent and course of the disease","volume":"16","author":"Canevari","year":"1975","journal-title":"Int J Cancer"},{"key":"2026010223413856300_oyaf410-B37","first-page":"189","article-title":"Clinical and immunological significance of human melanoma cytotoxic antibody","volume":"35","author":"Bodurtha","year":"1975","journal-title":"Cancer Res"},{"key":"2026010223413856300_oyaf410-B38","first-page":"1683","article-title":"Isolation and immunochemical characterization of antibodies from the sera of cancer patients which are reactive against human melanoma cell membranes by affinity chromatography","volume":"39","author":"Gupta","year":"1979","journal-title":"Cancer Res"},{"key":"2026010223413856300_oyaf410-B39","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1046\/j.1523-1747.1998.00354.x","article-title":"Antibody responses to melanoma\/melanocyte autoantigens in melanoma patients","volume":"111","author":"Huang","year":"1998","journal-title":"J Invest Dermatol"},{"key":"2026010223413856300_oyaf410-B40","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4049\/jimmunol.154.2.730","article-title":"Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen","volume":"154","author":"Hoon","year":"1995","journal-title":"J Immunol"},{"key":"2026010223413856300_oyaf410-B41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2133.1976.tb05147.x","article-title":"Melanoma cytoplasmic humoral antibody test. A diagnostic adjunct","volume":"94","author":"Copeman","year":"1976","journal-title":"Br J Dermatol"},{"key":"2026010223413856300_oyaf410-B42","first-page":"101","article-title":"Immunologic aspects of unknown primary melanoma","volume":"87","author":"Giuliano","year":"1980","journal-title":"Surgery"},{"key":"2026010223413856300_oyaf410-B43","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.1245\/s10434-014-3799-y","article-title":"Molecular characterization and patient outcome of melanoma nodal metastases and an unknown primary site","volume":"21","author":"Gos","year":"2014","journal-title":"Ann Surg Oncol"},{"key":"2026010223413856300_oyaf410-B44","doi-asserted-by":"crossref","first-page":"627527","DOI":"10.3389\/fonc.2021.627527","article-title":"Melanoma of unknown primary: evaluation of the characteristics, treatment strategies, prognostic factors in a monocentric retrospective study","volume":"11","author":"Del Fiore","year":"2021","journal-title":"Front Oncol"},{"key":"2026010223413856300_oyaf410-B45","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/annonc\/mdt411","article-title":"Metastatic melanoma of unknown primary resembles the genotype of cutaneous melanomas","volume":"25","author":"Egberts","year":"2014","journal-title":"Ann Oncol"},{"key":"2026010223413856300_oyaf410-B46","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1007\/s12094-021-02629-2","article-title":"Comparative genomic characterization of melanoma of known and unknown primary","volume":"23","author":"Rassy","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"2026010223413856300_oyaf410-B47","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1158\/2159-8290.CD-22-0603","article-title":"Comparative genomics provides etiologic and biological insight into melanoma subtypes","volume":"12","author":"Newell","year":"2022","journal-title":"Cancer Discov"},{"key":"2026010223413856300_oyaf410-B48","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/CMR.0000000000000048","article-title":"Melanomas of unknown primary frequently harbor TERT-promoter mutations","volume":"24","author":"Egberts","year":"2014","journal-title":"Melanoma Res"},{"key":"2026010223413856300_oyaf410-B49","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nature07586","article-title":"Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi","volume":"457","author":"Van Raamsdonk","year":"2009","journal-title":"Nature"},{"key":"2026010223413856300_oyaf410-B50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.2340\/00015555-2594","article-title":"GNA11-mutated and BAP1-negative melanomas ex blue naevi: a particularly aggressive entity","volume":"97","author":"Uguen","year":"2017","journal-title":"Acta Derm Venereol"},{"key":"2026010223413856300_oyaf410-B51","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/pcmr.12153","article-title":"Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma","volume":"26","author":"Dutton-Regester","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"2026010223413856300_oyaf410-B52","doi-asserted-by":"crossref","first-page":"103288","DOI":"10.1016\/j.critrevonc.2021.103288","article-title":"TERT promoter mutations and melanoma survival: a comprehensive literature review and meta-analysis","volume":"160","author":"Gandini","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"2026010223413856300_oyaf410-B53","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/s41467-018-03033-1","article-title":"Regulation of mutant TERT by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer","volume":"9","author":"Liu","year":"2018","journal-title":"Nat Commun"},{"key":"2026010223413856300_oyaf410-B54","doi-asserted-by":"crossref","first-page":"14402","DOI":"10.1073\/pnas.1611106113","article-title":"Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas","volume":"113","author":"Li","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026010223413856300_oyaf410-B55","doi-asserted-by":"crossref","first-page":"e0281487","DOI":"10.1371\/journal.pone.0281487","article-title":"TERT expression is associated with metastasis from thin primaries, exhausted CD4+ T cells in melanoma and with DNA repair across cancer entities","volume":"18","author":"Kuhn","year":"2023","journal-title":"PLoS One"},{"key":"2026010223413856300_oyaf410-B56","doi-asserted-by":"crossref","first-page":"7151","DOI":"10.1002\/cam4.3376","article-title":"TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment","volume":"9","author":"Li","year":"2020","journal-title":"Cancer Med"},{"key":"2026010223413856300_oyaf410-B57","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41419-024-06454-7","article-title":"The regulations of telomerase reverse transcriptase (TERT) in cancer","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"key":"2026010223413856300_oyaf410-B58","doi-asserted-by":"crossref","first-page":"e0256995","DOI":"10.1371\/journal.pone.0256995","article-title":"MiR-20a-5p functions as a potent tumor suppressor by targeting PPP6C in acute myeloid leukemia","volume":"16","author":"Bao","year":"2021","journal-title":"PLoS One"},{"key":"2026010223413856300_oyaf410-B59","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.cub.2005.01.031","article-title":"BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma","volume":"15","author":"Patton","year":"2005","journal-title":"Curr Biol"},{"key":"2026010223413856300_oyaf410-B60","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1021\/bi7022877","article-title":"Protein phosphatase 6 regulatory subunits composed of ankyrin repeat domains","volume":"47","author":"Stefansson","year":"2008","journal-title":"Biochemistry"},{"key":"2026010223413856300_oyaf410-B61","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.molmed.2006.07.008","article-title":"MITF: master regulator of melanocyte development and melanoma oncogene","volume":"12","author":"Levy","year":"2006","journal-title":"Trends Mol Med"},{"key":"2026010223413856300_oyaf410-B62","doi-asserted-by":"crossref","first-page":"5573","DOI":"10.1038\/s41598-022-08936-0","article-title":"PPP6C, a serine-threonine phosphatase, regulates melanocyte differentiation and contributes to melanoma tumorigenesis through modulation of MITF activity","volume":"12","author":"Maskin","year":"2022","journal-title":"Sci Rep"},{"key":"2026010223413856300_oyaf410-B63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16152675","article-title":"The leukemic isocitrate dehydrogenase (IDH) 1\/2 mutations impair myeloid and erythroid cell differentiation of primary human hematopoietic stem and progenitor cells (HSPCs)","volume":"16","author":"Pierangeli","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026010223413856300_oyaf410-B64","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/neuonc\/not087","article-title":"IDH1\/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma","volume":"15","author":"Zhang","year":"2013","journal-title":"Neuro Oncol"},{"key":"2026010223413856300_oyaf410-B65","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1111\/his.13707","article-title":"Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations","volume":"73","author":"Linos","year":"2018","journal-title":"Histopathology"},{"key":"2026010223413856300_oyaf410-B66","doi-asserted-by":"crossref","first-page":"e0169038","DOI":"10.1371\/journal.pone.0169038","article-title":"IDH1 R132H mutation enhances cell migration by activating AKT-mTOR signaling pathway, but sensitizes cells to 5-FU treatment as NADPH and GSH are reduced","volume":"12","author":"Zhu","year":"2017","journal-title":"PLoS One"},{"key":"2026010223413856300_oyaf410-B67","doi-asserted-by":"crossref","first-page":"21527","DOI":"10.1038\/s41598-024-72031-9","article-title":"MITF regulates IDH1, NNT, and a transcriptional program protecting melanoma from reactive oxygen species","volume":"14","author":"Roider","year":"2024","journal-title":"Sci Rep"},{"key":"2026010223413856300_oyaf410-B68","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.celrep.2017.05.014","article-title":"Cancer-Associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation","volume":"19","author":"Calvert","year":"2017","journal-title":"Cell Rep"},{"key":"2026010223413856300_oyaf410-B69","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/cancers7030849","article-title":"Treatment of regional metastatic melanoma of unknown primary origin","volume":"7","author":"van Beek","year":"2015","journal-title":"Cancers (Basel)"},{"key":"2026010223413856300_oyaf410-B70","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/cncr.21835","article-title":"Metastatic melanoma to lymph nodes in patients with unknown primary sites","volume":"106","author":"Cormier","year":"2006","journal-title":"Cancer"},{"key":"2026010223413856300_oyaf410-B71","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1245\/s10434-011-1801-5","article-title":"Outcome after therapeutic lymph node dissection in patients with unknown primary melanoma site","volume":"18","author":"Prens","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"2026010223413856300_oyaf410-B72","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1111\/ijd.16419","article-title":"Melanoma of unknown primary: favorable survival persists in the immunotherapy era","volume":"62","author":"Maharaj","year":"2023","journal-title":"Int J Dermatol"},{"key":"2026010223413856300_oyaf410-B73","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ijc.32229","article-title":"Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: a dutch population-based study","volume":"146","author":"Verver","year":"2020","journal-title":"Int J Cancer"},{"key":"2026010223413856300_oyaf410-B74","doi-asserted-by":"crossref","first-page":"9629","DOI":"10.1073\/pnas.1704371114","article-title":"Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma","volume":"114","author":"Duggan","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026010223413856300_oyaf410-B75","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s12079-020-00563-6","article-title":"In silico analyses of the tumor microenvironment highlight tumoral inflammation, a Th2 cytokine shift and a mesenchymal stem cell-like phenotype in advanced in basal cell carcinomas","volume":"14","author":"Lefran\u00e7ois","year":"2020","journal-title":"J Cell Commun Signal"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf410\/65877891\/oyaf410.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf410\/65877891\/oyaf410.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf410\/65877891\/oyaf410.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T04:41:55Z","timestamp":1767415315000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf410\/8379610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,13]]},"references-count":75,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf410","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,13]]},"article-number":"oyaf410"}}